Domestic surgical robot company EDGE MEDICAL-B (Stock Code: 02675.HK) commenced trading today on the main board of the Hong Kong Stock Exchange. The stock opened at HKD 59, marking a significant surge of 36.45% above its issue price of HKD 43.24. Excluding transaction fees, each board lot of 100 shares yielded a profit of HKD 1,576. Trading activity was also robust in the previous day's grey market, where the stock closed up 39.11% at HKD 60.15, generating a profit of HKD 1,691 per board lot.

The listing attracted substantial market attention. The Hong Kong public offering segment of EDGE MEDICAL was heavily oversubscribed by approximately 1,091.94 times. Due to the strong demand, the final number of shares allocated to the public offering was increased to 2.7723 million. Established in 2017, EDGE MEDICAL is a medical device company focused on the design, development, and manufacturing of surgical robots. The company's core products include the Edge Multi-Port Laparoscopic Surgical Robot and the Edge Single-Port Laparoscopic Surgical Robot for minimally invasive surgery. Their applications span several key areas, including urology, gynecology, and general surgery, with a commitment to enhancing surgical precision and accessibility through technological innovation. The company's financial data exhibits characteristics typical of high-growth biotech firms, combining rapid revenue expansion with substantial ongoing investment. Its revenue surged significantly from RMB 48 million in 2023 to RMB 160 million in 2024. Revenue for the first half of 2025 had already reached RMB 149.4 million, approaching the total for the full year 2024, indicating an accelerating commercialization process. However, due to persistent heavy investment in research and development, the company is not yet profitable, recording net losses of approximately RMB 213 million and RMB 219 million in 2023 and 2024, respectively. This reflects the long development cycles and high capital requirements inherent in the innovative medical device sector.